AI Portfolio Summary
In 2025 Q4, Sofinnova Investments, Inc. maintained a portfolio of 73 distinct positions. The most significant new addition to the portfolio was BRISTOL-MYERS SQUIBB, which now represents 3.52% of the total fund value. They heavily accumulated shares in JAZZ PHARMACEUTICALS, increasing their position by 63.0%. Conversely, Sofinnova Investments, Inc. completely exited their position in Gilead Sciences Inc.
Total Positions
73
Quarter
2025 Q4
Top Holding
NTRA (15.3%)
Top 10 Concentration
54.2%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 73
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NTRA
NATERA INC
|
Healthcare | 15.31% | 13.65% |
#1
Prev: #1
|
6.1 | no change | no change |
P
S
|
1,550,280 | $355,153,645 | 2018 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JAZZ
JAZZ PHARMACEUT...
|
Healthcare | 7.04% | 4.24% |
#2
3
Prev: #5
|
5.0 | 371,032 | 63.0% |
P
S
|
959,860 | $163,176,200 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AZN
ASTRAZENECA PLC
|
Healthcare | 6.47% | 3.46% |
#3
3
Prev: #6
|
4.9 | 808,401 | 98.1% |
P
S
|
1,632,334 | $150,060,465 | 2018 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 6.10% | 4.44% |
#4
1
Prev: #3
|
2.4 | no change | no change |
P
S
|
2,793,987 | $141,487,502 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMY
BRISTOL-MYERS S...
|
Healthcare | 3.52% | — |
#5
Prev: #—
|
3.4 | 1,512,994 | no change |
NEW
|
1,512,994 | $81,610,896 | 2018 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UTHR
UNITED THERAPEU...
|
Healthcare | 3.31% | 4.37% |
#6
2
Prev: #4
|
1.4 | -32,985 | -17.3% |
P
S
|
157,641 | $76,810,577 | 2019 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRTX
VERTEX PHARMACE...
|
Healthcare | 3.22% | 2.52% |
#7
7
Prev: #14
|
3.4 | 46,719 | 39.6% |
P
S
|
164,594 | $74,620,336 | 2019 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABBV
ABBVIE INC
|
Healthcare | 3.13% | 1.91% |
#8
11
Prev: #19
|
3.6 | 166,817 | 110.5% |
P
S
|
317,783 | $72,610,238 | 2019 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ISRG
INTUITIVE SURGI...
|
Healthcare | 3.10% | 2.71% |
#9
1
Prev: #10
|
3.3 | 16,072 | 14.5% |
P
S
|
126,968 | $71,909,596 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 3.02% | 1.67% |
#10
11
Prev: #21
|
1.2 | -154,316 | -7.3% |
P
S
|
1,973,625 | $70,103,160 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LLY
ELI LILLY & CO
|
Healthcare | 2.86% | — |
#11
Prev: #—
|
3.1 | 61,652 | no change |
NEW
|
61,652 | $66,256,171 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RAPP
RAPPORT THERAPE...
|
Healthcare | 2.49% | 3.16% |
#12
5
Prev: #7
|
1.0 | -43,171 | -2.2% |
P
S
|
1,904,408 | $57,779,739 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 2.38% | 2.36% |
#13
2
Prev: #15
|
1.0 | -111,399 | -13.4% |
P
S
|
720,448 | $55,107,068 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RNA
AVIDITY BIOSCIE...
|
Healthcare | 2.32% | 2.09% |
#14
4
Prev: #18
|
1.0 | -130,809 | -14.9% |
P
S
|
745,116 | $53,745,217 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 1.90% | 0.68% |
#15
25
Prev: #40
|
3.1 | 1,268,333 | 128.7% |
P
S
|
2,254,161 | $44,091,389 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMRN
BIOMARIN PHARMA...
|
Healthcare | 1.79% | — |
#16
Prev: #—
|
2.7 | 697,133 | no change |
NEW
|
697,133 | $41,430,614 | 2018 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APGE
APOGEE THERAPEU...
|
Healthcare | 1.74% | 1.23% |
#17
10
Prev: #27
|
0.7 | -30,572 | -5.4% |
P
S
|
534,845 | $40,370,101 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CDTX
CIDARA THERAPEU...
|
Healthcare | 1.72% | 0.28% |
#18
34
Prev: #52
|
3.0 | 126,068 | 232.6% |
P
S
|
180,265 | $39,818,736 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 1.60% | 0.50% |
#19
25
Prev: #44
|
0.7 | -47,111 | -27.3% |
P
S
|
125,722 | $37,055,302 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMTX
IMMATICS N.V
|
Healthcare | 1.56% | 1.04% |
#20
9
Prev: #29
|
2.8 | 1,207,705 | 54.2% |
P
S
|
3,435,542 | $36,073,191 | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INBX
INHIBRX BIOSCIE...
|
Healthcare | 1.55% | 0.81% |
#21
16
Prev: #37
|
2.6 | 14,565 | 3.3% |
P
S
|
454,657 | $35,917,903 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMNM
IMMUNOME INC
|
Healthcare | 1.50% | 0.28% |
#22
31
Prev: #53
|
2.9 | 1,182,426 | 271.2% |
P
S
|
1,618,477 | $34,764,886 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AVBP
ARRIVENT BIOPHA...
|
Healthcare | 1.47% | 1.71% |
#23
3
Prev: #20
|
0.6 | no change | no change |
P
S
|
1,696,752 | $34,138,650 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GKOS
GLAUKOS CORP
|
Healthcare | 1.40% | 1.40% |
#24
1
Prev: #23
|
0.6 | -24,866 | -7.9% |
P
S
|
288,128 | $32,532,532 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IDYA
IDEAYA BIOSCIEN...
|
Healthcare | 1.32% | 1.37% |
#25
1
Prev: #24
|
0.5 | -37,574 | -4.1% |
P
S
|
885,121 | $30,598,633 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GILD
Gilead Sciences...
|
Healthcare | 0.00% | 7.60% |
Sold All 😨
(Was: #2) |
0.3 | -1,252,312 | -100.0% |
CLOSED
|
— | $— | 2018 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BSX
Boston Scientif...
|
Healthcare | 0.00% | 3.04% |
Sold All 😨
(Was: #8) |
0.3 | -569,427 | -100.0% |
CLOSED
|
— | $— | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IBB
PUT
iShares TR
|
PUT Option | 0.00% | 2.57% |
Sold All 😨
(Was: #13) |
0.3 | -325,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UTHR
PUT
United Therapeu...
|
PUT Option | 0.00% | 2.23% |
Sold All 😨
(Was: #16) |
0.3 | -97,100 | -100.0% |
CLOSED
|
— | $— | 2019 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XBI
PUT
SPDR Series Tru...
|
PUT Option | 0.00% | 2.19% |
Sold All 😨
(Was: #17) |
0.3 | -400,000 | -100.0% |
CLOSED
|
— | $— | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QURE
PUT
Uniqure NV
|
PUT Option | 0.00% | 1.60% |
Sold All 😨
(Was: #22) |
0.3 | -500,000 | -100.0% |
CLOSED
|
— | $— | 2019 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AKRO
Akero Therapeut...
|
Healthcare | 0.00% | 1.23% |
Sold All 😨
(Was: #26) |
0.3 | -473,625 | -100.0% |
CLOSED
|
— | $— | 2020 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SMMT
CALL
Summit Therapeu...
|
CALL Option | 0.00% | 1.02% |
Sold All 😨
(Was: #30) |
0.3 | -900,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QURE
CALL
Uniqure NV
|
CALL Option | 0.00% | 0.96% |
Sold All 😨
(Was: #33) |
0.3 | -300,000 | -100.0% |
CLOSED
|
— | $— | 2019 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRUS
Merus N V
|
Healthcare | 0.00% | 0.86% |
Sold All 😨
(Was: #35) |
0.3 | -166,729 | -100.0% |
CLOSED
|
— | $— | 2018 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PTCT
PTC Therapeutic...
|
Healthcare | 0.00% | 0.63% |
Sold All 😨
(Was: #41) |
0.3 | -186,932 | -100.0% |
CLOSED
|
— | $— | 2018 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LQDA
PUT
Liquidia Corpor...
|
PUT Option | 0.00% | 0.31% |
Sold All 😨
(Was: #51) |
0.3 | -250,000 | -100.0% |
CLOSED
|
— | $— | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SRRK
Scholar Rock Hl...
|
Healthcare | 0.00% | 0.06% |
Sold All 😨
(Was: #56) |
0.3 | -31,410 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 73 holdings